Aktis Oncology (NASDAQ:AKTS) Sets New 12-Month High – What’s Next?

Aktis Oncology (NASDAQ:AKTS) shares reached a new 52-week high on Thursday . The company traded as high as $29.50 and last traded at $30.7050, with a volume of 828 shares trading hands. The stock had previously closed at $28.70.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on AKTS. Raymond James Financial assumed coverage on shares of Aktis Oncology in a research note on Monday, June 15th. They set a “strong-buy” rating and a $40.00 price target for the company. Weiss Ratings upgraded Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday. HC Wainwright increased their price objective on Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. Finally, William Blair assumed coverage on Aktis Oncology in a research note on Wednesday, April 29th. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Aktis Oncology currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.00.

Aktis Oncology Stock Performance

The stock’s 50 day moving average is $20.40.

Aktis Oncology (NASDAQ:AKTS) last announced its earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share for the quarter. The business had revenue of $1.87 million during the quarter. Analysts expect that Aktis Oncology will post -1.62 EPS for the current year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.